Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

27.45USD
22 Nov 2017
Change (% chg)

$0.41 (+1.52%)
Prev Close
$27.04
Open
$27.08
Day's High
$27.59
Day's Low
$26.58
Volume
182,962
Avg. Vol
329,692
52-wk High
$55.30
52-wk Low
$24.68

Select another date:

Thu, Nov 2 2017

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

BRIEF-Radius Health receives FDA fast track designation for elacestrant

* Radius health receives fda fast track designation for elacestrant (rad1901)

BRIEF-Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer

* Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer

BRIEF-Radius Health prices $300 mln of 3 pct convertible senior notes due 2024

* Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024

BRIEF-Radius Health announces proposed public offering of $300 million of convertible senior notes due 2024

* Radius Health - to use net proceeds to support U.S. commercial launch of Tymlos injection, development of its life cycle management activities​ Source text for Eikon: Further company coverage:

BRIEF-Radius Health reports Q2 loss per share $1.58

* Radius Health reports second quarter 2017 financial and operating results and provides business update

BRIEF-Radius Health appoints Jesper Høiland as president and CEO

* Radius Health appoints Jesper Høiland as president and chief executive officer to lead the next stage of growth and value creation as a fully integrated commercial biotech company

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

Select another date: